Abstract Library

#617 Incidence and Geographic Distribution of Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs): A Systematic Review of the Literature

Introduction: Based on the literature, the world-wide incidence of neuroendocrine tumors (NETs) seems to be increasing, however, a systematic literature overview is lacking.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Fraenkel M

Authors: Fraenkel M, Kim M, Faggiano A, De Herder W, Valk G,

Keywords: neuroendocrine tumor, epidemiology, incidence,

#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue

Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Fraenkel M, Barak D, Appelbaum L, Krausz Y, Gross D,

Keywords: metastatic type one gastric carcinoid, somatostatin analogue,

#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience

Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Glaser B, Barak D, Fraenkel M, Gross D,

Keywords: MEN-1, hyperparathyroidism, pituitary tumors, gastroenteropancreatic tumors, menin,

#101 Chronic Complications of Peptide Receptor Radionuclide Therapy (PRRT)- A Single Center Experience

Introduction: In the last decade, a new treatment modality, peptide receptor radionuclide therapy (PPRT), has been introduced for gastroenteropancreatic neuroendocrine tumor (GEPNET) patients with non-resectable or progressive disease. PRRT has been associated with several complications, including bone marrow suppression, renal toxicity and hepatic damage.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Fraenkel M, Barak D, Mueller-Brand J, Krausz Y, Glaser B,

Keywords: PRRT, chronic complications, GEPNET,

#21 Peptide Receptor Radioligand Therapy (PRRT) is an Effective Treatment for the Long-Term Stabilization of Malignant Gastrinomas

Introduction: Gastrinomas represent a rare group of neuroendocrine tumors usually located in the duodenum or pancreas. They secrete gastrin, which is responsible for the clinical picture of severe acid-related peptic disease and diarrhea, known as the Zollinger-Ellison syndrome (ZES). While symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs) treatment, little data is known regarding the possible anti-tumor effect of the peptide receptor radioligand therapy (PRRT) in gastrinoma patients.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grozinsky-Glasberg S, Barak D, Fraenkel M, Müeller J, Shimon I,

Keywords: PRRT, malignant gastrinoma, treatment, anti-tumor effect ,